Publications



2017

Herrmann A.; Lahtz C.; Nagao T.; Song J.Y.; Chan W.C.; Lee H.; Yue C.; Look T.; Muelfarth R.; Li W.; Jenkins K.; Williams J.; Budde L.E.; Forman S.J.; Kwak L.W.; Blankenstein T.; Yu H.
CTLA4 promotes Tyk2-STAT3 dependent B cell oncogenecity
Cancer Research : (2017-07-17)



Kunert A.; Obenaus M.; Lamers C.H.J.; Blankenstein T.; Debets R.
T cell receptors for clinical therapy: in vitro assessment of toxicity risk
Clinical Cancer Research : (2017-06-23)



Kammertoens T.; Friese C.; Arina A.; Idel C.; Briesemeister D.; Rothe M.; Ivanov A.; Szymborska A.; Patone G.; Kunz S.; Sommermeyer D.; Engels B.; Leisegang M.; Textor A.; Fehling H.J.; Fruttiger M.; Lohoff M.; Herrmann A.; Yu H.; Weichselbaum R.; Uckert W.; Huebner N.; Gerhardt H.; Beule D.; Schreiber H.; Blankenstein T.
Tumour ischaemia by interferon-{gamma} resembles physiological blood vessel regression
Nature 545 (7652): 98-102 (2017-05-04)



Grosheva A.S.; Zharkov D.O.; Stahl J.; Gopanenko Al.V.; Tupikin A.E.; Kabilov M.R.; Graifer D.M.; Karpova G.G.
Recognition but no repair of abasic site in single-stranded DNA by human ribosomal uS3 protein residing within intact 40S subunit
Nucleic Acids Research 45 (7): 3833-3843 (2017-04-20)



Miller N.J.; Church C.D.; Dong L.; Crispin D.; Fitzgibbon M.P.; Lachance K.; Jing L.; Shinohara M.; Gavvovidis I.; Willimsky G.; McIntosh M.; Blankenstein T.; Koelle D.M.; Nghiem P.
Tumor-infiltrating merkel cell polyomavirus-specific T cells are diverse and associated with improved patient survival
Cancer Immunology Research 5 (2): 137-147 (2017-02)



2016

Textor A.; Schmidt K.; Kloetzel P.M.; Weissbrich B.; Perez C.; Charo J.; Anders K.; Sidney J.; Sette A.; Schumacher T.N.M.; Keller C.; Busch D.H.; Seifert U.; Blankenstein T.
Preventing tumor escape by targeting a post-proteasomal trimming independent epitope
Journal of Experimental Medicine 213 (11): 2333-2348 (2016-10-17)



Kieback E.; Hilgenberg E.; Stervbo U.; Lampropoulou V.; Shen P.; Bunse M.; Jaimes Y.; Boudinot P.; Radbruch A.; Klemm U.; Kuehl A.A.; Liblau R.; Hoevelmeyer N.; Anderton S.M.; Uckert W.; Fillatreau S.
Thymus-derived regulatory T cells are positively selected on natural self-antigen through cognate interactions of high functional avidity
Immunity 44 (5): 1114-1126 (2016-05-17)



Blankenstein T.
Receptor combinations hone T-cell therapy
Nature Biotechnology 34 (4): 389-391 (2016-04-07)



Leisegang M.; Kammertoens T.; Uckert W.; Blankenstein T.
Targeting human melanoma neoantigens by T cell receptor gene therapy
Journal of Clinical Investigation 126 (3): 854-858 (2016-03-01)



2015

Obenaus M.; Leitao C.; Leisegang M.; Chen X.; Gavvovidis I.; van der Bruggen P.; Uckert W.; Schendel D.J.; Blankenstein T.
Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice
Nature Biotechnology 33 (4): 402-407 (2015-04)



Blankenstein T.; Leisegang M.; Uckert W.; Schreiber H.
Targeting cancer-specific mutations by T cell receptor gene therapy
Current Opinion in Immunology 33: 112-119 (2015-04)



Walsh J.T.; Hendrix S.; Boato F.; Smirnov I.; Zheng J.; Lukens J.R.; Gadani S.; Hechler D.; Goelz G.; Rosenberger K.; Kammertoens T.; Vogt J.; Vogelaar C.; Siffrin V.; Radjavi A.; Fernandez-Castaneda A.; Gaultier A.; Gold R.; Kanneganti T.D.; Nitsch R.; Zipp F.; Kipnis J.
MHCII-independent CD4+ T cells protect injured CNS neurons via IL-4
Journal of Clinical Investigation 125 (2): 699-714 (2015-02-02)



2014

Textor A.; Listopad J.J.; Wuehrmann L.L.; Perez C.; Kruschinski A.; Chmielewski M.; Abken H.; Blankenstein T.; Charo J.
Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFN{gamma}
Cancer Research 74 (23): 6796-6805 (2014-12-01)



2013

Linnemann C.; Heemskerk B.; Kvistborg P.; Kluin R.J.C.; Bolotin D.A.; Chen X.; Bresser K.; Nieuwland M.; Schotte R.; Michels S.; Gomez-Eerland R.; Jahn L.; Hombrink P.; Legrand N.; Shu C.J.; Mamedov I.Z.; Velds A.; Blank C.U.; Haanen J.B.A.G.; Turchaninova M.A.; Kerkhoven R.M.; Spits H.; Hadrup S.R.; Heemskerk M.H.M.; Blankenstein T.; Chudakov D.M.; Bendle G.M.; Schumacher T.N.M.
High-throughput identification of antigen-specific TCRs by TCR gene capture
Nature Medicine 19 (11): 1534-1541 (2013-11)



Li L.; Blankenstein T.
Generation of transgenic mice with megabase-sized human yeast artificial chromosomes by yeast spheroplast-embryonic stem cell fusion
Nature Protocols 8 (8): 1567-1582 (2013-08)



Hess Michelini R.; Manzo T.; Sturmheit T.; Basso V.; Rocchi M.; Freschi M.; Listopad J.J.; Blankenstein T.; Bellone M.; Mondino A.
Vaccine-instructed intratumoral IFN-{gamma} enables regression of autochthonous mouse prostate cancer in allogeneic T cell transplantation
Cancer Research 73 (15): 4641-4652 (2013-08-01)



Zhang J; Chen L; Liu X; Kammertoens T.; Blankenstein T.; Qin Z.
Fibroblast-specific protein 1/S100A4-positive cells prevent carcinoma through collagen production and encapsulation of carcinogens
Cancer Research 73 (9): 2770-2781 (2013-05-01)



Kammertoens T.; Blankenstein T.
It's the peptide-MHC affinity, stupid
Cancer Cell 23 (4): 429-431 (2013-04-15)



Schmidt K.; Zilio S.; Schmollinger J.C.; Bronte V.; Blankenstein T.; Willimsky G.
Differently immunogenic cancers in mice induce immature myeloid cells that suppress CTL in vitro but not in vivo following transfer
Blood 121 (10): 1740-1748 (2013-03-07)



Willimsky G.; Schmidt K.; Loddenkemper C.; Gellermann J.; Blankenstein T.
Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance
Journal of Clinical Investigation 123 (3): 1032-1043 (2013-03-01)



Listopad J.J.; Kammertoens T.; Anders K.; Silkenstedt B.; Willimsky G.; Schmidt K.; Kuehl A.A.; Loddenkemper C.; Blankenstein T.
Fas expression by tumor stroma is required for cancer eradication
Proceedings of the National Academy of Sciences of the United States of America 110 (6): 2276-2281 (2013-02-05)



Anders K.; Blankenstein T.
Molecular pathways: comparing the effects of drugs and T cells to effectively target oncogenes
Clinical Cancer Research 19 (2): 320-326 (2013-01-15)



2012

Blankenstein T.; Coulie P.G.; Gilboa E.; Jaffee E.M.
The determinants of tumour immunogenicity
Nature Reviews Cancer 12 (4): 307-313 (2012-04)



2011

Anders K.; Buschow C.; Herrmann A.; Milojkovic A.; Loddenkemper C.; Kammertoens T.; Daniel P.; Yu H.; Charo J.; Blankenstein T.
Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer
Cancer Cell 20 (6): 755-767 (2011-12-13)



Popovic J.; Li L.P.; Kloetzel P.M.; Leisegang M.; Uckert W.; Blankenstein T.
The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed
Blood 118 (4): 946-954 (2011-07-28)



2010

Czeh M.; Loddenkemper C.; Shalapour S.; Schoen C.; Robine S.; Goldscheid E.; Stein H.; Schueler T.; Willimsky G.; Blankenstein T.
The immune response to sporadic colorectal cancer in a novel mouse model
Oncogene 29 (50): 6591-6602 (2010-12-16)



Hayashida N.; Fujimoto M.; Tan K.; Prakasam R.; Shinkawa T.; Li L.; Ichikawa H.; Takii R.; Nakai A.
Heat shock factor 1 ameliorates proteotoxicity in cooperation with the transcription factor NFAT
EMBO Journal 29 (20): 3459-3469 (2010-10-20)



Li L.P.; Lampert J.C.; Chen X.; Leitao C.; Popovic J.; Mueller W.; Blankenstein T.
Transgenic mice with a diverse human T cell antigen receptor repertoire
Nature Medicine 16 (9): 1029-1034 (2010-09)



Leisegang M.; Turqueti-Neves A.; Engels B.; Blankenstein T.; Schendel D.J.; Uckert W.; Noessner E.
T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy
Clinical Cancer Research 16 (8): 2333-2343 (2010-04-15)



2009

Wolf S.A.; Steiner B.; Wengner A.M.; Lipp M.; Kammertoens T.; Kempermann G.
Adaptive peripheral immune response increases proliferation of neural precursor cells in the adult hippocampus
FASEB Journal 23 (9): 3121-3128 (2009-09)



Babaylova E.; Graifer D.; Malygin A.; Stahl J.; Shatsky I.; Karpova G.
Positioning of subdomain IIId and apical loop of domain II of the hepatitis C IRES on the human 40S ribosome
Nucleic Acids Research 37 (4): 1141-1151 (2009-03)



2008

Kruschinski A.; Moosmann A.; Poschke I.; Norell H.; Chmielewski M.; Seliger B.; Kiessling R.; Blankenstein T.; Abken H.; Charo J.
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas
Proceedings of the National Academy of Sciences of the United States of America 105 (45): 17481-17486 (2008-11-11)



Willimsky G.; Czeh M.; Loddenkemper C.; Gellermann J.; Schmidt K.; Wust P.; Stein H.; Blankenstein T.
Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness
Journal of Experimental Medicine 205 (7): 1687-1700 (2008-07-07)



Kieback E.; Charo J.; Sommermeyer D.; Blankenstein T.; Uckert W.
A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer
Proceedings of the National Academy of Sciences of the United States of America 105 (2): 623-628 (2008-01-15)



2007

Willimsky G.; Blankenstein T.
The adaptive immune response to sporadic cancer
Immunological Reviews 220 (1): 102-112 (2007-12)



Nassenstein C.; Kammertoens T.; Veres T.Z.; Uckert W.; Spies E.; Fuchs B.; Krug N.; Braun A.
Neuroimmune crosstalk in asthma: dual role of the neurotrophin receptor p75NTR
Journal of Allergy and Clinical Immunology 120 (5): 1089-1096 (2007-11)



Cayeux S.; Bukarica B.; Buschow C.; Charo J.; Bunse M.; Doerken B.; Blankenstein T.
In vivo splenic CD11c cells downregulate CD4 T-cell response thereby decreasing systemic immunity to gene-modified tumour cell vaccine
Gene Therapy 14 (20): 1481-1491 (2007-10)



Blankenstein T.
Do autochthonous tumors interfere with effector T cell responses?
Seminars in Cancer Biology 17 (4): 267-274 (2007-08)



Zhao X.; Mohaupt M.; Jiang J.; Liu S.; Li B.; Qin Z.
Tumor necrosis factor receptor 2-mediated tumor suppression is nitric oxide dependent and involves angiostasis
Cancer Research 67 (9): 4443-4450 (2007-05-01)



Varga G.; Balkow S.; Wild M.K.; Stadtbaeumer A.; Krummen M.; Rothoeft T.; Higuchi T.; Beissert S.; Wethmar K.; Scharffetter-Kochanek K.; Vestweber D.; Grabbe S.
Active MAC-1 (CD11b/CD18) on DC is inhibitory for full T cell activation
Blood 109 (2): 661-669 (2007-01-15)



2005

Willimsky G.; Blankenstein T.
Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance
Nature 437 (7055): 141-146 (2005-09-01)



Kammertoens T.; Willebrand R.; Erdmann B.; Li L.; Li Y.; Engels B.; Uckert W.; Blankenstein T.
CY15, a malignant histiocytic tumor that is phenotypically similar to immature dendritic cells
Cancer Research 65: 2560-2564 (2005-01-01)



Blankenstein T.
The role of tumor stroma in the interaction between tumor and immune system
Current Opinion in Immunology 17 (2): 180-186 (2005-01-01)



2004

Ohl L.; Mohaupt M.; Czeloth N.; Hintzen G.; Kiafard Z.; Zwirner J.; Blankenstein T.; Henning G.; Foerster R.
CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions
Immunity 21 (2): 279-288 (2004-08-01)



Stelljes M.; Strothotte R.; Pauels H.G.; Poremba C.; Milse M.; Specht C.; Albring J.; Bisping G.; Scheffold C.; Kammertoens T.; Oelmann E.; Silling G.; Berdel W.E.; Kienast J.
Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets
Blood 104 (4): 1210-1216 (2004-01-01)



Qin Z.H.; Blankenstein T.
A cancer immunosurveillance controversy
Nature Immunology 5 (1): 3-4 (2004-01-01)



2003

Schueler T.; Koernig S.; Blankenstein T.
Tumor rejection by modulation of tumor stromal fibroblasts
Journal of Experimental Medicine 198 (10): 1487-1493 (2003-11-17)



Blankenstein T.; Qin Z.H.
The role of IFN-gamma in tumor transplantation immunity and inhibition of chemical carcinogenesis
Current Opinion in Immunology 15 (2): 148-154 (2003-04)



Aicher A.; Heeschen C.; Mohaupt M.; Cooke J.P.; Zeiher A.M.; Dimmeler S.
Nicotine strongly activates dendritic cell-mediated adaptive immunity - Potential role for progression of atherosclerotic lesions
Circulation 107 (4): 604-611 (2003-02-04)



Qin Z.H.; Schwartzkopff J.; Pradera F.; Kammertoens T.; Seliger B.; Pircher H.; Blankenstein T.
A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8T cells
Cancer Research 63 (14): 4095-4100 (2003-01-01)



Blankenstein T.; Qin Z.
Chemical carcinogens as foreign bodies and some pitfalls regarding cancer immune surveillance
Advances in Cancer Research 90: 179-207 (2003)



2002

Qin Z.; Kim H.J.; Hemme J.; Blankenstein T.
Inhibition of methylcholanthrene-induced carcinogenesis by an interferon gamma receptor-dependent foreign body reaction
Journal of Experimental Medicine 195 (11): 1479-1490 (2002-06-03)



Qin Z.; Harders C.; Cao X.; Huber C.; Blankenstein T.; Seliger B.
Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumors
Cancer Research 62 (10): 2856-2860 (2002-05-15)



Blankenstein T.; Schueler T.
Cross-priming versus cross-tolerance: are two signals enough?
Trends in Immunology 23 (4): 171-173 (2002-04-01)



2001

Schueler T.; Kammertoens T.; Preiss S.; Debs P.; Noben-Trauth N.; Blankenstein T.
Generation of tumor-associated cytotoxic T lymphocytes requires interleukin 4 from CD8+ T cells
Journal of Experimental Medicine 194 (12): 1767-1775 (2001-12-17)



Ibe S.; Qin Z.H.; Schueler T.; Preiss S.; Blankenstein T.
Tumor rejection by disturbing tumor stroma cell interactions
Journal of Experimental Medicine 194 (11): 1549-1559 (2001-12-03)



Michelsen K.S.; Aicher A.; Mohaupt M.; Hartung T.; Dimmeler S.; Kirschning C.J.; Schumann R.R.
The role of toll-like receptors (TLRs) in bacteria-induced maturation of murine dendritic cells (DCS). Peptidoglycan and lipoteichoic acid are inducers of DC maturation and require TLR2
Journal of Biological Chemistry 276 (28): 25680-25686 (2001-07-13)



Cayeux S.; Qin Z.H.; Doerken B.; Blankenstein T.
Decreased generation of anti-tumor immunity after intrasplenic immunization
European Journal of Immunology 31 (5): 1392-1399 (2001-01-01)



Becker C.; Pohla H.; Frankenberger B.; Schueler T.; Assenmacher M.; Schendel D.J.; Blankenstein T.
Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay
Nature Medicine 7 (10): 1159-1162 (2001-01-01)



Seliger B.; Wollscheid U.; Momburg F.; Blankenstein T.; Huber C.
Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells
Cancer Research 61: 1095-1099 (2001-01-01)



Yun T.J.; Tallquist M.D.; Aicher A.; Rafferty K.L.; Marshall A.J.; Moon J.J.; Ewings M.K.; Mohaupt M.; Herring S.W.; Clark E.A.
Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function
Journal of Immunology 166: 1482-1491 (2001-01-01)



2000

Schendel D.J.; Frankenberger B.; Jantzer P.; Cayeux S.; Noessner E.; Willimsky G.; Maget B.; Pohla H.; Blankenstein T.
Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse
Gene Therapy 7 (23): 2007-2014 (2000-12-01)



Qin Z.H.; Blankenstein T.
CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNgamma receptor expression by nonhematopoietic cells
Immunity 12 (6): 677-686 (2000-06-01)



Willimsky G.; Blankenstein T.
Interleukin-7/B7.1-encoding adenoviruses induce rejection of transplanted but not nontransplanted tumors
Cancer Research 60 (3): 685-692 (2000-02-01)



Beltinger C.; Fulda S.; Kammertoens T.; Uckert W.; Debatin K.M.
Mitochondrial amplification of death signals determines thymidine kinase/ ganciclovir-triggered activation of apoptosis
Cancer Research 60 (12): 3212-3217 (2000-01-01)



1999

Beltinger C.; Fulda S.; Kammertoens T.; Meyer E.; Uckert W.; Debatin K.M.
Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases
Proceedings of the National Academy of Sciences of the United States of America 96: 8699-8704 (1999-07-20)



Schueler T.; Qin Z.; Ibe S.; Noben-Trauth N.; Blankenstein T.
T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice
Journal of Experimental Medicine 189 (5): 803-810 (1999-03-01)



Cayeux S.; Qin Z.; Doerken B.; Blankenstein T.
Vaccines using gene-modified tumor cells
Gene therapy :Principles and Applications : 283-298 (1999-01-01)



Cayeux S.; Richter G.; Becker C.; Pezzutto A.; Doerken B.; Blankenstein T.
Direct and indirect T cell priming by dendritic cell vaccines
European Journal of Immunology 29: 225-234 (1999-01-01)



1998

Petersson M.; Charo J.; Salazar-Onfray F.; Noffz G.; Mohaupt M.; Qin Z.H.; Klein G.; Blankenstein T.; Kiessling R.
Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-11
Journal of Immunology 161: 2099-2105 (1998-09-01)



Lange C.; Schueler T.; Blankenstein T.
Interleukin 4 gene-defective mice reconstituted with wild-type bone marrow fail to produce normal immunoglobulin E levels
Journal of Experimental Medicine 187 (9): 1487-1493 (1998-05-04)



Qin Z.H.; Richter G.; Schueler T.; Ibe S.; Cao X.T.; Blankenstein T.
B cells inhibit induction of T cell-dependent tumor immunity
Nature Medicine 4: 627-630 (1998-01-01)



Westermann J.; Aicher A.; Qin Z.; Cayeux S.; Daemen K.; Blankenstein T.; Doerken B.; Pezzutto A.
Retroviral interleukin-7 gene transfer into human dendritic cells enhances T cell activation
Gene Therapy 5: 264-271 (1998-01-01)



Noffz G.; Qin Z.H.; Kopf M.; Blankenstein T.
Neutrophils but not eosinophils are involved in growth suppression of IL-4-secreting tumors
Journal of Immunology 160: 345-350 (1998-01-01)



Jung D.; Jaeger E.; Cayeux S.; Blankenstein T.; Hilmes C.; Karbach J.; Moebius U.; Knuth A.; Huber C.; Seliger B.
Strong immunogenic potential of a B7 retroviral expression vector: Generation of HLA-B7-restricted CTL response against selectable marker genes
Human Gene Therapy 9: 53-62 (1998-01-01)



Daniel P.T.; Kroidl A.; Cayeux S.; Scholz C.; Sturm I.; Blankenstein T.; Pezzutto A.; Doerken B.
Retroviral B7.1 gene transfer in cancer cells protects cytotoxic T cells from deletion by "veto" apoptosis
Advances in Experimental Medicine and Biology 451: 265-276 (1998-01-01)



1997

Daniel P.T.; Kroidl A.; Cayeux S.; Bargou R.C.; Blankenstein T.; Doerken B.
Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis
Journal of Immunology 159 (8): 3808-3815 (1997-10-15)



Cayeux S.; Doerken B.; Blankenstein T.
Tumor cell vaccines using genetically modified cells coexpressing cytokines and the T cell costimulatory molecule B7
Concepts in Gene Therapy : 487-503 (1997-01-01)



Cayeux S.; Richter G.; Becker C.; Beck C.; Aicher A.; Pezzutto A.; Doerken B.; Blankenstein T.
Lack of correlation between rejection of tumor cells co-expressing interleukin 2 and B7.1 and vaccine efficiency
European Journal of Immunology 27: 1657-1662 (1997-01-01)



Aicher A.; Westermann J.; Cayeux S.; Willimsky G.; Daemen K.; Blankenstein T.; Uckert W.; Doerken B.; Pezzutto A.
Successful retroviral mediated transduction of a receptor gene in human dendritic cells: feasibility of therapy with gene-modified antigen presenting cells
Experimental Hematology 25: 39-44 (1997-01-01)



Cayeux S.; Richter G.; Noffz G.; Doerken B.; Blankenstein T.
Influence of gene modified (IL 7, IL 4, and B7) tumor cell vaccines on tumor antigen presentation
Journal of Immunology 158: 2834-2841 (1997-01-01)



1996

Cayeux S.; Beck C.; Doerken B.; Blankenstein T.
Coexpression of interleukin-4 and B7.1 in murine tumor cells leads to improved tumor rejection and vaccine effect compared to single gene transfectants and a classical adjuvant
Human Gene Therapy 7 (4): 525-529 (1996-01-01)



Blankenstein T.; Cayeux S.; Qin Z.
Genetic approaches to cancer immunotherapy
Reviews of Physiology Biochemistry and Pharmacology 129: 1-49 (1996-01-01)



Blankenstein T.; Qin Z.
Cancer vaccines in gene therapy
Gene Therapy 3 (2): 95-96 (1996-01-01)



Brocke S.; Gijbels K.; Allegretta M.; Ferber I.; Piercy C.; Blankenstein T.; Martin R.; Utz U.; Karin N.; Mitchell D.; Veromaa T.; Waisman A.; Gaur A.; Conlon P.; Ling N.; Fairchild P.J.; Wraith D.C.; Ogarra A.; Fathman C.G.; Steinman L.
Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein
Nature 379 (6563): 343-346 (1996-01-01)



1995

Beck C.; Cayeux S.; Lupton S.; Doerken B.; Blankenstein T.
The thymidine kinase/ganciclovir-mediated "suicide" effect is highly variable in different tumor cells
Human Gene Therapy 6 (12): 1525-1530 (1995-01-01)



Cayeux S.; Beck C.; Aicher A.; Doerken B.; Blankenstein T.
Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines
European Journal of Immunology 25 (8): 2325-2331 (1995-01-01)



Qin Z.; Blankenstein T.
Tumor growth inhibition mediated by lymphotoxin: evidence of B lymphocyte involvement in the antitumor response
Cancer Research 55 (21): 4747-4751 (1995-01-01)



Salazar-Onfray F.; Petersson M.; Franksson L.; Matsuda M.; Blankenstein T.; Karre K.; Kiessling R.
IL-10 converts mouse lymphoma cells to a CTL-resistant, nk-sensitive phenotype with low but peptide-inducible MHC class I expression
Journal of Immunology 154 (12): 6291-6298 (1995-01-01)



Qin Z.; van Tits L.J.H.; Buurman W.A.; Blankenstein T.
Human lymphotoxin has at least equal antitumor activity in comparison to human tumor necrosis factor but is less toxic in mice
Blood 85: 2779-2785 (1995-01-01)



1993

Qin Z.; Krueger-Krasagakes S.; Kunzendorf U.; Hock H.; Diamantstein T.; Blankenstein T.
Expression of tumor necrosis factor by different tumor cell lines results either in tumor suppression or augmented metastasis
Journal of Experimental Medicine 178 (1): 355-360 (1993-07-01)



Hock H.; Dorsch M.; Kunzendorf U.; Qin Z.; Diamantstein T.; Blankenstein T.
Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon-gamma
Proceedings of the National Academy of Sciences of the United States of America 90 (7): 2774-2778 (1993-04-01)